Researchers at the National Cancer Institute in Warsaw have made a significant contribution to an international study on the treatment of metastatic renal cell carcinoma. The completed ICARO-RC project included one of the largest patient analyses in the world, and the results were published in the prestigious journal Clinical Genitourinary Cancer.
Polish scientists co-author groundbreaking study to treat kidney cancer
Published June 18, 2025 07:34
fot. Piotr Wójcik
An important international study on the treatment of metastatic renal cell carcinoma, ICARO-RC (International Consortium for the Analysis of Real-world Outcomes in Renal Cancer), co-authored by experts from the Maria Sklodowska-Curie National Cancer Institute - National Research Institute in Warsaw, has concluded.
Three leading cancer centers participated in the project: the Polish National Cancer Institute, Masaryk Memorial Cancer Institute in Brno and La Paz University Hospital in Madrid. Data from daily clinical practice in Poland and the Czech Republic were analyzed, covering the second largest patient population in the world.
The study, the results of which have just been published in the prestigious journal Clinical Genitourinary Cancer, examined the efficacy of cabozantinib, an oral tyrosine kinase inhibitor, in the first-line treatment of patients with advanced renal cell carcinoma.
The results confirmed that cabozantinib treatment in real-world clinical settings has good therapeutic effects and a predictable side effect profile. Particularly important was the inclusion of patients with rare histological tumor types, a group for which there had been insufficient data from classical clinical trials to date.
- This is an important step toward more personalized treatment for patients with renal cell carcinoma, comments Professor Jakub Kucharz, first author of the publication and head of the Behavioral Unit of the Urinary Tract Tumor Clinic at the Warsaw Institute.
The ICARO consortium promises to continue the collaboration and is already working on further research projects to further improve cancer therapies based on data from actual clinical practice.
Source: NIO
